Your browser doesn't support javascript.
Clinical evaluation of the antibody response in patients with COVID-19 using automated high-throughput immunoassays.
Kubota, Katsumi; Kitagawa, Yutaro; Matsuoka, Masaru; Imai, Kazuo; Orihara, Yuta; Kawamura, Rieko; Sakai, Jun; Ishibashi, Noriomi; Tarumoto, Norihito; Takeuchi, Shinichi; Maesaki, Shigefumi; Maeda, Takuya.
  • Kubota K; Department of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
  • Kitagawa Y; Department of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
  • Matsuoka M; Department of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
  • Imai K; Department of Infectious Disease and Infection Control, Saitama Medical University, Saitama, Japan.
  • Orihara Y; Department of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
  • Kawamura R; Department of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
  • Sakai J; Department of Infectious Disease and Infection Control, Saitama Medical University, Saitama, Japan.
  • Ishibashi N; Department of Infectious Disease and Infection Control, Saitama Medical University, Saitama, Japan.
  • Tarumoto N; Department of Infectious Disease and Infection Control, Saitama Medical University, Saitama, Japan.
  • Takeuchi S; Department of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
  • Maesaki S; Department of Infectious Disease and Infection Control, Saitama Medical University, Saitama, Japan.
  • Maeda T; Department of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan; Department of Laboratory Medicine, Saitama Medical University, Saitama, Japan. Electronic address: t_maeda@saitama-med.ac.jp.
Diagn Microbiol Infect Dis ; 100(3): 115370, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-1128955
ABSTRACT
Several automated high-throughput immunoassays for detecting anti-SARS-CoV-2 antibodies by a semi-quantitative approach have been commercialized. In this study, we describe the timeline of the antibody response in patients with RT-PCR-confirmed COVID-19. A total of 292 sequential serum samples from 33 Japanese patients were retrospectively analyzed using four test kits for SARS-CoV-2 the Abbott SARS-CoV-2 IgG assay (Abbott), Elecsys® Anti-SARS-CoV-2 assay (Roche Diagnostic), and VITROS® Anti-SARS-CoV-2 Total and IgG assays (Ortho Clinical Diagnostics). All automated immunoassays could equivalently identify positive sera collected within 2 weeks after symptom onset (99.3%-100%). In addition, the S protein-based automated immunoassay, the VITROS® Anti-SARS-CoV-2 Total assay, may play a complementary role in evaluating passive antibody therapies or vaccines against SARS-CoV-2, although further research is required.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Serological Testing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Diagn Microbiol Infect Dis Year: 2021 Document Type: Article Affiliation country: J.diagmicrobio.2021.115370

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Serological Testing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Diagn Microbiol Infect Dis Year: 2021 Document Type: Article Affiliation country: J.diagmicrobio.2021.115370